Cagrilintide Mechanism of Action

Introduction

Cagrilintide is a long-acting acylated amylin analog that engages the calcitonin receptor (CTR) and the three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) — a family of heterodimeric G protein-coupled receptors (GPCRs) formed by the CTR core complexed with receptor activity-modifying proteins (RAMPs). Understanding the molecular pharmacology of cagrilintide requires first establishing the structural biology of the amylin receptor family and then examining published data on how cagrilintide's distinct chemical modifications alter receptor binding dynamics relative to native amylin and other calcitonin-family peptides.

Receptor Targets and Signaling Pathways

The amylin receptor family comprises three receptor complexes: AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3). Each complex is formed by the non-covalent association of the CTR — a class B1 GPCR — with one of three RAMP accessory subunits. Hay and colleagues (2004) established that RAMP incorporation into the CTR complex is required for the characteristic high-affinity amylin binding phenotype, and that CTR alone has substantially lower amylin potency [1]. The three RAMP subunits confer different pharmacological properties on the resulting receptor heterodimer.

At the intracellular signaling level, all three amylin receptor subtypes couple primarily to Gs proteins, stimulating adenylyl cyclase and generating cyclic AMP (cAMP) as a second messenger. Research published in Science Signaling (2024) reported that RAMP subunit identity also modulates receptor signaling efficiency and the balance between Gs-mediated cAMP generation and beta-arrestin recruitment, indicating that the three RAMP subtypes do not produce identical downstream pharmacology even when activated by the same ligand [2]. A full summary of the controlled clinical trial literature on cagrilintide is available in the cagrilintide published research article.

Reported Molecular Interactions

Cagrilintide binds to CTR and all three AMYR subtypes as a non-selective agonist. A 2025 study in Nature Communications used cryo-electron microscopy to determine structures of cagrilintide bound to Gs-coupled active states of AMY1R, AMY2R, AMY3R, and CTR, comparing these to structures of the same receptors bound to rat amylin, salmon calcitonin, and other amylin-class peptides [3].

The structural analysis identified several molecular features specific to cagrilintide's binding mode. An intra-peptide ionic interaction between residues R17 and E14 in cagrilintide — designated the "R17Cagri–E14Cagri ionic lock" — was reported to energetically favor formation of a predominant bypass conformation at the CTR. This conformation, combined with a proline substitution at position 37 (P37) and the N-terminal C20 fatty acid acylation, was proposed to underlie cagrilintide's improved receptor potency compared to unmodified amylin [3].

At the AMY1R, AMY2R, and AMY3R subtypes, cagrilintide was observed to adopt a conserved bypass binding orientation characteristic of amylin-class peptides. However, the C-terminal P37 substitution introduced AMYR-subtype-specific differences in the dynamics of the extracellular domain (ECD) protomers — components contributed by the RAMP subunit — indicating that the proline modification alters receptor dynamics in a manner that differs across the three subtypes [3].

The N-terminal acylation moiety of cagrilintide, which extends the pharmacokinetic half-life by enabling albumin binding, was reported to influence receptor complex dynamics without abolishing the amylin-like binding mode at any of the four receptor types characterized [3].

Downstream Effects in Research Models

A 2025 study published in eBioMedicine investigated which amylin receptor subtypes mediate cagrilintide's in vivo effects on body weight using RAMP-knockout mouse models [4]. The researchers reported that cagrilintide's body weight effects were absent or substantially attenuated in mice lacking RAMP1 (the defining subunit of AMY1R) and RAMP3 (the defining subunit of AMY3R), whereas mice lacking RAMP2 (AMY2R) retained the compound's weight-related effects. These findings led the authors to conclude that AMY1R and AMY3R, localized to brain regions relevant to energy homeostasis signaling, mediate the predominant pharmacodynamic response to cagrilintide. By contrast, salmon calcitonin — which activates CTR more selectively — did not replicate the same in vivo weight profile in these models and in some conditions produced opposing effects, demonstrating that CTR activation alone is not sufficient to explain cagrilintide's pharmacological profile [4].

The preclinical development chemistry report by Andreassen and colleagues (2021) reported that cagrilintide reduced food intake in rat models for several days at nanomolar doses per kilogram, while the earlier amylin analog pramlintide required orders-of-magnitude higher doses to achieve shorter-lived and smaller effects [5]. The authors attributed the difference to cagrilintide's extended plasma half-life rather than to intrinsically different receptor affinity, though the structural work noted above suggests that binding mode differences also contribute.

Active Research Directions

The structural characterization of cagrilintide's receptor interactions published in 2025 [3] has opened several productive lines of mechanistic inquiry. The relative contribution of peripheral versus central AMY1R and AMY3R populations to the compound's in vivo effects is an active area of investigation, as the RAMP-knockout study [4] identified brain receptor populations as primary mediators in murine models and ongoing work is evaluating translatability to higher mammalian systems.

The downstream signaling consequences of cagrilintide's subtype-specific extracellular domain dynamics — identified by cryo-EM structural analysis [3] — remain an emerging research frontier. Characterizing whether the differential RAMP ECD dynamics correspond to differences in receptor internalization kinetics, G protein coupling efficiency, or receptor desensitization in human tissue contexts represents a productive direction for receptor pharmacology investigation. Similarly, the molecular basis for the additive pharmacological profile observed when cagrilintide is combined with GLP-1 receptor agonists in clinical trials is an open question guiding ongoing research into shared and distinct neural circuit engagement between the two receptor classes. The GLP-1/GIP dual agonist tirzepatide represents a related incretin pharmacology context in which combination receptor strategies have been characterized at the molecular level. Research-grade cagrilintide from SpartaLabs is supplied with batch-specific HPLC purity and mass spectrometry data for use in receptor pharmacology investigations.

References

1. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004;32(5):865–867. PMID: 15494035. DOI: 10.1042/BST0320865

2. Darbalaei S, Bhaskara RM, Harris PWR, Brimble MA, Bhatt DL, Bhattacharya S, et al. Amylin receptor subunit interactions are modulated by agonists and determine signaling. Sci Signal. 2024;17(860):eadt8127. PMID: 39416010. DOI: 10.1126/scisignal.adt8127

3. Deganutti G, Atanasio S, Bhatt DL, Igonet S, Koehl A, Bhattacharya S, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun. 2025;16:3389. PMID: 40204768. DOI: 10.1038/s41467-025-58680-y

4. Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025;105836. PMC12270663. DOI: 10.1016/j.ebiom.2025.105836

5. Andreassen KV, Feigh M, Hjuler ST, Christoffersen BØ, Damgaard Møller A, Rolin B, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183–11194. DOI: 10.1021/acs.jmedchem.1c00565